
MANAGEMENT OF ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA

POCKET GUIDE



GLOBAL PRIMARY CARE EDUCATION

BASED ON THE 2007 ARIA WORKSHOP REPORT AND THE IPAG HANDBOOK
In collaboration with WHO, GA²LEN, AllerGen, and Wonca

THE PURPOSE OF THIS GUIDE

This document was prepared by the Wonca Expert Panel, including Bousquet J, Reid J, Van Weel C, Baena Cagnani C, Demoly P, Denburg J, Fokkens WJ, Grouse L, Mullol K, Ohta K, Schermer T, Valovirta E, and Zhong N. It was edited by Dmitry Nonikov. This material is based on the IPAG Handbook and the ARIA Workshop Report, in collaboration with the World Health Organization, GA²LEN (Global Allergy and Asthma European Network), AllerGen, International Primary Care Respiratory Group (IPCRG), European Federation of Allergy and Airways Diseases Patients Associations (EFA), and the World Organization of Family Doctors (Wonca).

Management that follows evidence-based practice guidelines yields better patient results. However, global evidence-based practice guidelines are often complicated and recommend the use of resources often not available in the primary care setting worldwide. The joint Wonca/GARD expert panel offers support to primary care physicians worldwide by distilling the existing evidence based recommendations into this brief reference guide. The guide lists diagnostic and therapeutic measures that can be carried out worldwide in the primary care environment and in this way provide the best possible care for patients with allergic rhinitis. The material presented in sections 1-5 will assist you in diagnosing and treating allergic rhinitis.

PRIMARY CARE CHALLENGE

Allergic rhinitis is a growing primary care challenge since most patients consult primary care physicians. General practitioners play a major role in the management of allergic rhinitis as they make the diagnosis, start the treatment, give the relevant information, and monitor most of the patients. In some countries, general practitioners perform skin prick tests. Studies in Holland and the UK found that common nasal allergies can be diagnosed with a high certainty using simple diagnostic criteria. Nurses may also play an important role in the identification of allergic diseases including allergic rhinitis in the primary care of developing countries and in schools. In addition, many patients with allergic rhinitis have concomitant asthma and this must be checked.

ALLERGIC RHINITIS RECOMMENDATIONS

- 1- Allergic rhinitis is a major chronic respiratory disease due to its:
 - Prevalence
 - Impact on quality-of-life
 - Impact on work/school performance and productivity
 - Economic burden
 - Links with asthma
- 2- In addition, allergic rhinitis is associated with co-morbidities such as conjunctivitis.
- 3- Allergic rhinitis should be considered as a risk factor for asthma along with other known risk factors.
- 4- A new subdivision of allergic rhinitis has been proposed:
 - Intermittent (IAR)
 - Persistent (PER)
- 5- The severity of allergic rhinitis has been classified as "mild" or "moderate/severe" depending on the severity of symptoms and quality-of-life outcomes.
- 6- Depending on the subdivision and severity of allergic rhinitis, a stepwise therapeutic approach has been proposed.
- 7- The treatment of allergic rhinitis combines:
 - Pharmacotherapy
 - Immunotherapy
 - Education
- 8- Patients with persistent allergic rhinitis should be evaluated for asthma by means of a medical history, chest examination, and, if possible and when necessary, the assessment of airflow obstruction before and after bronchodilator.
- 9- Patients with asthma should be appropriately evaluated (history and physical examination) for rhinitis.
- 10- Ideally, a combined strategy should be used to treat the upper and lower airway diseases to optimize efficacy and safety.

1- RECOGNIZE ALLERGIC RHINITIS

ALLERGIC RHINITIS QUESTIONNAIRE¹

Instructions: To evaluate the possibility of allergic rhinitis, start by asking the questions below to patients with nasal symptoms.

This questionnaire contains the questions related to allergic rhinitis symptoms that have been identified in peer-reviewed literature as having the greatest diagnostic value. It will not produce a definitive diagnosis, but may enable you to determine whether a diagnosis of allergic rhinitis should be further investigated or is unlikely.

| Allergic Rhinitis Questionnaire | |
|--|------------------|
| Question | Response Choices |
| 1. Do you have any of the following symptoms? | |
| • Symptoms on only one side of your nose | Yes No |
| • Thick, green or yellow discharge from your nose (see NOTE) | Yes No |
| • Postnasal drip (down the back of your throat) with thick mucus and/or runny nose (see NOTE) | Yes No |
| • Facial pain (see NOTE) | Yes No |
| • Recurrent nosebleeds | Yes No |
| • Loss of smell (see NOTE) | Yes No |
| 2. Do you have any of the following symptoms for at least one hour on most days (or on most days during the season if your symptoms are seasonal)? | |
| • Watery runny nose | Yes No |
| • Sneezing, especially violent and in bouts | Yes No |
| • Nasal obstruction | Yes No |
| • Nasal itching | Yes No |
| • Conjunctivitis (red, itchy eyes) | Yes No |

Evaluation:

- The symptoms described in Question 1 are usually NOT found in allergic rhinitis. The presence of ANY ONE of them suggests that alternative diagnoses should be investigated. Consider alternative diagnoses and/or referral to a specialist.
- NOTE: Purulent discharge, postnasal drip, facial pain, and loss of smell are common symptoms of sinusitis. Because most patients with sinusitis also have rhinitis (though not always allergic in origin), in this situation the clinician should also evaluate the possibility of allergic rhinitis.
- The presence of watery runny nose with ONE OR MORE of the other symptoms listed in Question 2 suggests allergic rhinitis, and indicates that the patient should undergo further diagnostic assessment.
- The presence of watery runny nose ALONE suggests that the patient MAY have allergic rhinitis. (Additionally, some patients with allergic rhinitis have only nasal obstruction as a cardinal symptom.)
- If the patient has sneezing, nasal itching, and/or conjunctivitis, but NOT watery runny nose, consider alternative diagnoses and/or referral to a specialist.
- In adults with late-onset rhinitis, consider and query occupational causes. Occupational rhinitis frequently precedes or accompanies the development of occupational asthma. Patients in whom an occupational association is suspected should be referred to a specialist for further objective testing and assessment.


ALLERGIC RHINITIS DIAGNOSIS GUIDE¹

Instructions: In patients of all ages with lower nasal symptoms only, whose responses to the Allergic Rhinitis Questionnaire suggest that this diagnosis should be investigated, use this guide to help you evaluate the possibility of allergic rhinitis. All of the diagnostic investigations presented in this guide may not be available in all areas; in most cases, the combination of those diagnostic investigations that are available and the individual health care professional's clinical judgement will lead to a robust clinical diagnosis. This guide is intended to supplement, not replace, a complete physical examination and thorough medical history.


| Allergic Rhinitis Diagnosis Guide | |
|---|---|
| Diagnostic Tool | Findings that Support Diagnosis |
| Physical examination | Transverse crease of nose, allergic shiners, allergic salute. |
| In persistent rhinitis: <ul style="list-style-type: none"> • anterior rhinoscopy using speculum and mirror gives limited but often valuable information • nasal endoscopy (usually performed by specialist) may be needed to exclude other causes of rhinitis, nasal polyps, and anatomic abnormalities | Exclusion of other causes. |
| Trial of therapy | Improvement with antihistamines or intranasal glucocorticosteroid. |
| Allergy skin testing or measurement of allergen-specific IgE in serum (if symptoms are persistent and/or moderate/severe, or if quality of life is affected) | <ul style="list-style-type: none"> • Confirm presence of atopy. • Specific triggers identified. |
| Nasal challenge tests (if occupational rhinitis suspected) | Confirm sensitivity to specific triggers. |

¹International Primary Care Airways Group (IPAG) Handbook available at <http://www.globalfamilydoctor.com>.

2- DIFFERENTIAL DIAGNOSIS OF ALLERGIC RHINITIS²




3- MAKE THE DIAGNOSIS OF ALLERGIC RHINITIS²



²Allergic Rhinitis and its impact on Asthma (ARIA) 2007. Full text ARIA documents and resources: <http://www.wheiar.org>.

4- CLASSIFY ALLERGIC RHINITIS²



5- TREAT ALLERGIC RHINITIS

Treatment Goals

Goals for the treatment of rhinitis assume accurate diagnosis and assessment of severity as well as any link with asthma in an individual patient. Goals include:

- Unimpaired sleep
- Ability to undertake normal daily activities, including work and school attendance, without limitation or impairment, and the ability to participate fully in sport and leisure activities
- No troublesome symptoms
- No or minimal side-effects of rhinitis treatment

STRENGTH OF EVIDENCE FOR EFFICACY OF RHINITIS TREATMENT²


| ARIA 2007 | | | | | |
|-----------------------------|--------|------------|--------|----------|-----|
| Intervention | SAR | | PAR | | PER |
| | adults | children | adults | children | |
| Oral H1 Antihistamine | A | A | A | A | A |
| Intranasal H1 Antihistamine | A | A | A | A | A** |
| Intranasal CS | A | A | A | A | A** |
| Intranasal cromone | A | A | A | A | A |
| LTRAs | A | A (>6 yrs) | A | A | A** |
| Subcutaneous SIT | A | A | A | A | A** |
| Sublingual / nasal SIT | A | A | A | B | A** |
| Allergen avoidance | D | D | A* | B* | |

SAR - Seasonal Allergic Rhinitis
 PAR - Perennial Allergic Rhinitis
 PER - Persistent Allergic Rhinitis
 CS - Corticosteroids
 LTRAs - Anti-Leukotrienes
 SIT - Specific Immunotherapy

*not effective in the general population
 **extrapolated from studies in SAR/PAR

²Allergic Rhinitis and its impact on Asthma (ARIA) 2007. Full text ARIA documents and resources: <http://www.whiar.org>.

DIAGNOSIS AND SEVERITY ASSESSMENT OF ALLERGIC RHINITIS²



Allergen and irritant avoidance may be appropriate

If conjunctivitis add:
oral H1-antihistamine
or intraocular H1-antihistamine
or intraocular cromone
(or saline)


Consider specific immunotherapy

PEDIATRIC ASPECTS

Allergic rhinitis is part of the "allergic march" during childhood but intermittent allergic rhinitis is unusual before two years of age. Allergic rhinitis is most prevalent during school age years. In preschool children, the diagnosis of AR is difficult. In school children and adolescents, the principles of treatment are the same as for adults, but doses may be adapted, and special care should be taken to avoid the side effects of treatments typical in this age group.

²Allergic Rhinitis and its impact on Asthma (ARIA) 2007. Full text ARIA documents and resources: <http://www.whear.org>.

6- ASSESS POSSIBILITY OF ASTHMA²



GLOSSARY OF RHINITIS MEDICATIONS¹

| Name and Also known as | Generic name | Mechanism of action | Side effects | Comments |
|---|--|--|--|--|
| Oral H₁ antihistamines H₁-blockers | 2nd generation Cetirizine Ebastine Fexofenadine Loratadine Mizolastine Acrivastine Azelastine Mequitazine New products Desloratadine Levocetirizine Rupatadine | - blockage of H ₁ receptor - some anti-allergic activity - new generation drugs can be used once daily - no development of tachyphylaxis | 2nd generation - no sedation for most drugs - no anti-cholinergic effect - no cardiotoxicity - acrivastine has sedative effects - oral azelastine may induce sedation and a bitter taste | - First-line therapy except in Moderate/ Severe Persistent Allergic Rhinitis - 2nd generation oral H ₁ -blockers are preferred for their favorable efficacy/safety ratio and pharmacokinetics; first generation molecules are no longer recommended because of their unfavorable safety/efficacy ratio - Rapidly effective (less than 1hr) on nasal and ocular symptoms - Moderately effective on nasal congestion * Cardiotoxic drugs (astemizole, terfenadine) are no longer marketed in most countries |
| Local H₁ antihistamines (intranasal, intraocular) | Azelastine Levocabastine Olopatadine | - blockage of H ₁ receptor - some anti-allergic activity for azelastine | - Minor local side effects - Azelastine: bitter taste in some patients | Rapidly effective (less than 30 min) on nasal or ocular symptoms |
| Intranasal glucocorticosteroids | Beclomethasone dipropionate Budesonide Ciclesonide Flunisolide Fluticasone propionate Fluticasone furoate Mometasone furoate Triamcinolone acetonide | - potentially reduce nasal inflammation - reduce nasal hyperreactivity | - Minor local side effects - Wide margin for systemic side effects - Growth concerns with BDP only - In young children consider the combination of intranasal and inhaled drugs | - The most effective pharmacologic treatment of allergic rhinitis; first-line treatment for Moderate/ Severe Persistent Allergic Rhinitis - Effective on nasal congestion - Effective on smell - Effect observed after 6-12 hrs but maximal effect after a few days - Patients should be advised on the proper method of administering intranasal glucocorticosteroids, including the importance of directing the spray laterally rather than medially (toward the septum) in the nose |

¹International Primary Care Airways Group (IPAG) Handbook available at <http://www.globalfamilydoctor.com>.

²Allergic Rhinitis and its impact on Asthma (ARIA) 2007. Full text ARIA documents and resources: <http://www.whiar.org>.

| | | | | |
|---|--|--|--|--|
| Oral / IM glucocorticosteroids | Dexamethasone Hydrocortisone Methylprednisolone Prednisolone Prednisone Triamcinolone Betamethasone Deflazacort | - Potently reduce nasal inflammation - Reduce nasal hyperreactivity | - Systemic side effects common in particular for IM drugs - Depot injections may cause local tissue atrophy | When possible, intranasal glucocorticosteroids should replace oral or IM drugs However, a short course of oral glucocorticosteroids may be needed if moderate/severe symptoms |
| Local cromones (intranasal, intraocular) | Cromoglycate Nedocromil Naaga | - mechanism of action poorly known | - Minor local side effects | Intraocular cromones are very effective Intranasal cromones are less effective and their effect is short lasting Overall excellent safety |
| Oral decongestants | Ephedrine Phenylephrine Phenylpropranolamine Pseudoephedrine Oral H1-antihistamine-decongestant combination | - sympathomimetic drug - relieve symptoms of nasal congestion | - Hypertension - Palpitations - Restlessness - Agitation - Tremor - Insomnia - Headache - Dry mucous membranes - Urinary retention - Exacerbation of glaucoma or thyrotoxicosis | Use oral decongestants with caution in patients with heart disease Oral H1-antihistamine decongestant combination products may be more effective than either product alone but side effects are combined |
| Intranasal decongestants | Oxymethazoline <i>Others</i> | - sympathomimetic drugs - relieve symptoms of nasal congestion | - Same side effects as oral decongestants but less intense Rhinitis medicamentosa is a rebound phenomenon occurring with prolonged use (over 10 days) | Act more rapidly and more effectively than oral decongestants Limit duration of treatment to less than 10 days to avoid rhinitis medicamentosa |
| Intranasal anti-cholinergics | Ipratropium | - anticholinergics block almost exclusively rhinorrhea | - Minor local side effects - Almost no systemic anticholinergic activity | Effective in allergic and nonallergic patients with rhinorrhea |
| CysLT antagonists Antileukotrienes | Montelukast Pranlukast Zafirlukast | - Block CysLT receptor | Excellent tolerance | Effective on rhinitis and asthma Effective on all symptoms of rhinitis and on ocular symptoms |

References: 1) International Primary Care Airways Group (IPAG) Handbook available at <http://www.globalfamilydoctor.com>.
2) Allergic Rhinitis and its impact on Asthma (ARIA) 2007. Full text ARIA documents and resources: <http://www.whiar.org>.

GINA materials have been used with permission from the Global Initiative for Asthma (www.ginasthma.org). Material from the IPAG Handbook has been used with permission from the International Primary Care Airways Group.

The printing of this ARIA Pocket Guide has been supported by an educational grant from:

The ARIA Initiative has been supported by educational grants from:

| | |
|-----------------|-----------------|
| ALK Abelló | Nycomed |
| GlaxoSmithKline | Phadia |
| Grupo Uriach | Sanofi Aventis |
| Meda Pharma | Schering-Plough |
| MSD | Stallergenes |
| Novartis | UCB |

ARIA source documents are at www.whiar.org

© MCR Inc.

Copies of this document are available at www.us-health-network.com